Adoption and implementation of new technologies in substance abuse treatment
Adoption and implementation of new technologies in substance abuse treatment
复制标题
DOI：
10.1016/s0740-5472(02)00241-6
复制
发表时间：
2002-06-01
影响因子：
3.9
通讯作者：
Johnson, JA
中科院分区：
文献类型：
--
作者：
Roman, PM;Johnson, JA
除了临床结果外，了解采用和实施新的治疗干预措施也是至关重要的。这一分析旨在评估组织一级的特征在了解药物滥用治疗中新技术的采用和实施方面的预测性效用。纳曲酮被选为研究的合适样本技术，在400个私人药物滥用治疗中心的全国样本中，目前有44.1%的人在使用纳曲酮。纳曲酮的采用与治疗中心的年龄和行政领导密切相关。纳曲酮的采用也与管理保健计划覆盖的中心工作量的百分比以及病例工作量中复发者的百分比显著相关。这项分析在预测纳曲酮对初级酒精依赖或初级阿片成瘾的应用方面不太成功。(C)2002 Elsevier Science Inc.保留所有权利。
in addition to clinical outcomes, understanding the adoption and implementation of new treatment interventions is essential. This analysis was designed to assess the predictive utility of organization-level features in understanding the adoption and implementation of new technologies in substance abuse treatment. Naltrexone, which was found to be in current use in 44.1% of a national sample of 400 private substance abuse treatment centers, was selected as an appropriate sample technology for study. Adoption of naltrexone is significantly related to both the treatment center's age and its administrative leadership. Naltrexone adoption is also significantly associated with the percentage of the center's caseload covered by managed care programs and by the percentage of relapsers represented in the caseload. The analysis was less successful in predicting naltrexone implementation for either primary alcohol dependence or primary opiate addiction. (C) 2002 Elsevier Science Inc. All rights reserved.